Vascodagama Online Journal

Molluscum Contagiosum Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Molluscum Contagiosum Pipeline Landscape

 Breaking News
  • No posts were found

Molluscum Contagiosum Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Molluscum Contagiosum Pipeline Landscape

November 30
02:38 2022
Molluscum Contagiosum Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Molluscum Contagiosum Pipeline Landscape

DelveInsight’s, “Molluscum Contagiosum Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Molluscum Contagiosum pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In the Molluscum Contagiosum pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Molluscum Contagiosum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Recent Developmental Activities in the Molluscum Contagiosum Pipeline

  • Novans’ new drug candidate, SB 206 is a topically administered drug molecule in development for the treatment of molluscum contagiosum. The phase I and II data demonstrated that SB 206 for the treatment of molluscum contagiosum has beneficial effects on the infection. The drug works on the nitric oxide mechanism of action, where it act as nitric oxide donor to subsequently destroy the virus.
  • Veloce’s drug VBP-245 is currently being evaluated for the treatment of Molluscum Contagiosum and has demonstrated good safety and efficacy profile in phase I trials. VBP-245 is an antiviral drug that inhibits the HN protein responsible for virus attachment to the host cells.

 

Key takeaways from the Molluscum Contagiosum Pipeline Insight Report

  • DelveInsight’s Molluscum Contagiosum Pipeline analysis depicts the space with 10+ active players working to develop 10+ pipeline therapies.
  • The Molluscum Contagiosum pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.
  • Molluscum Contagiosum Pipeline Companies such as Novan, Veloce Biopharma, Verrica Pharmaceuticals, Santalis Healthcare, and others.
  • Molluscum Contagiosum Pipeline therapies such as SB206 4%, SB206 8%, SB206 12%, VBP-245 Topical Gel, and others.
  • The Molluscum Contagiosum Companies and academics are working to assess challenges and seek opportunities that could influence Molluscum Contagiosum R&D. The therapies under development are focused on novel approaches to treat/improve Molluscum Contagiosum.

 

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Molluscum Contagiosum Pipeline Outlook Report

 

Molluscum Contagiosum Overview

Molluscum Contagiosum is a common viral infection of skin that is characterized by pinkish, firm, round, and painless bumps over the skin. The size of the bump can vary from a few mm to 2-5 mm in diameter. The disease is caused by poxvirus Molluscum contagiosum. The lesion becomes red, swollen, and itchy at times and can spread to other areas of the body when scratched (autoinoculation). The disease can spread from person to person through physical contact or contaminated fomites. Though the molluscum contagiosum is common, the persons with weakened immune system, atopic dermatitis, or inhabiting in warm, moist, and crowded places are more prone to the infection. The infection is not age –specific but is most common in children with 1-10 years of age.

 

 Molluscum Contagiosum Emerging Drugs

  • SB 206 (Berdazimer Sodium): Novan Inc
  • VBP-245 (Povidone Iodine Topical): Veloce Biopharma

 

Molluscum Contagiosum Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Molluscum Contagiosum. The companies which have their Molluscum Contagiosum drug candidates in the most advanced stage, i.e. phase III include, Novan Inc.

 

Find out more about Molluscum Contagiosum treatment drugs @ Molluscum Contagiosum Clinical Trials Analysis

 

Molluscum Contagiosum Pipeline development activities

The Molluscum Contagiosum pipeline report provides insights into:

  • All of the companies that are developing therapies for the treatment of Molluscum Contagiosum with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Glaucoma
  • Molluscum Contagiosum key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Molluscum Contagiosum

The Molluscum Contagiosum Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Scope of the Molluscum Contagiosum Pipeline Report

  • Coverage- Global
  • Molluscum Contagiosum Pipeline Companies- Novan, Veloce Biopharma, Verrica Pharmaceuticals, Santalis Healthcare, and others.
  • Molluscum Contagiosum Pipeline therapies- SB206 4%, SB206 8%, SB206 12%, VBP-245 Topical Gel, and others

 

Table of Content

  1. Introduction
  2. Molluscum Contagiosum Executive Summary
  3. Molluscum Contagiosum: Overview
  4. Molluscum Contagiosum Pipeline Therapeutics
  5. Molluscum Contagiosum Therapeutic Assessment
  6. Molluscum Contagiosum – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Molluscum Contagiosum Collaboration Deals
  9. Late Stage Products (Phase III)
  10. SB 206 (Berdazimer Sodium): Novan
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. VBP-245 (Povidone Iodine Topical): Veloce Biopharma
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Molluscum Contagiosum Analyst Views
  20. Molluscum Contagiosum Key Companies
  21. Appendix

 

Download Sample PDF Report for Molluscum Contagiosum clinical trials advancements @ Molluscum Contagiosum Emerging Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/